Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

GP350 CAR-T Cells for Relapse/Refractory and Epstein-Barr Virus Infection Associated Lymphoid Neoplasms, an Open-label, Single-arm Clinical Trial

NCT07306156 is registered in ClinicalTrials.gov with Zhimin Zhai as lead sponsor.

NCT NCT07306156
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07306156 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
GP350 CAR-T Cells for Relapse/Refractory and Epstein-Barr Virus Infection Associated Lymphoid Neoplasms, an Open-label, Single-arm Clinical Trial
Lead sponsor
Zhimin Zhai
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 10, 2025
Completion date
November 20, 2032
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ebv associated lymphoid neoplasms